Bayer HealthCare Pharmaceuticals Inc., of Whippany, N.J., began enrollment in a trial studying Xofigo (radium Ra 223 dichloride) injection in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer.